2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
Zengin Z, Pal S, McDermott D, Escudier B, Hutson T, Porta C, Verzoni E, Atkins M, Kasturi V, Rini B. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clinical Genitourinary Cancer 2022, 20: 553-557. PMID: 36096984, DOI: 10.1016/j.clgc.2022.08.005.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaDose modificationSorafenib armAdverse eventsCell carcinomaVascular endothelial growth factor receptor inhibitorEndothelial growth factor receptor inhibitorImproved progression-free survivalGrowth factor receptor inhibitorsProgression-free survivalDuration of toxicityMeasurable diseaseOpen labelFree survivalPrimary endpointTreatment discontinuationTreatment armsReceptor inhibitorsDose reductionKidney cancerTRAEsPatientsTivozanibSorafenib
2020
Tivozanib in renal cell carcinoma: a new approach to previously treated disease
Salgia N, Zengin Z, Pal S. Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances In Medical Oncology 2020, 12: 1758835920923818. PMID: 32547647, PMCID: PMC7249546, DOI: 10.1177/1758835920923818.Peer-Reviewed Original ResearchPhase III trialsIII trialsMulti-institutional phase III trialVascular endothelial growth factor receptor tyrosine kinasesEarly clinical trialsRenal cell carcinomaManagement of RCCVEGF-TKICell carcinomaClinical trialsTargeted therapyTreatment paradigmMultikinase inhibitorClinical dataFurther trialsGrowth factor receptor tyrosine kinaseTivozanibDisease settingsClinical toolReceptor tyrosine kinasesTrialsRCCTherapyTyrosine kinaseCarcinoma